EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Clinical and economic burden associated with symptomatic and asymptomatic obstructive hypertrophic cardiomyopathy in Germany

Farbod Sedaghat-Hamedani, Carla L Zema, Michael Schultze, Tarcyane B Garcia, Nils Kossack, Julia Borchert, Ervant J Maksabedian Hernandez, Yue Zhong, Tobias Bluhmki, Taryn Krause, Johanna Schmoelders, Benjamin Meder

Clinical Research in Cardiology · 2025

DOI: 10.1007/s00392-025-02776-4 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Research in Cardiology, 2025. Verfasst von Farbod Sedaghat-Hamedani und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, Institute of Cardiomyopathies, University of Heidelberg, INF 410, 69120, Heidelberg, Germany. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Cost of Illness, Health Care Costs. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers Squibb, Medizinische Fakultät Heidelberg der Universität Heidelberg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The clinical and economic burden of obstructive hypertrophic cardiomyopathy (HCM) in Germany for symptomatic versus asymptomatic patients has not been comprehensively assessed.

Methods

This retrospective observational study analyzed nationally representative WIG2 Benchmark Database data, identifying adults diagnosed with obstructive HCM from 2012 to 2018. Study index was the first date when a participant met eligibility criteria. An algorithm based on coded symptoms and pharmacological treatments was used to divide patients into symptomatic and asymptomatic subgroups. Annual prevalence, patient characteristics, outcomes, resource utilization, and costs were assessed during follow-up.

Results

Overall, 1141 patients were included (649 symptomatic patients and 492 asymptomatic patients during the 1-year pre-index period [baseline]). In total, 1042 patients had symptomatic disease at some point during follow-up. Annual obstructive HCM prevalence increased between 2011 and 2019 and was higher for symptomatic than asymptomatic patients. Compared with asymptomatic patients, symptomatic patients: were older (mean age: 62.8 vs. 55.5 years), were less likely to be male (59% vs. 67%), and had higher Charlson Comorbidity Index (mean: 2.82 vs. 1.69) at baseline; had higher rates of all-cause mortality (0.05 vs. 0.02 per 100 patient-years) and cardiovascular events (mean follow-up: 4.7 years); had more outpatient visits (13.3 vs. 10.8 per patient-year [PPY]), inpatient visits (0.7 vs. 0.5 PPY), and longer mean length of stay (8.7 vs. 7.4 days); and had higher mean costs PPY for outpatient, inpatient, and pharmacy services (total: €5975 vs. €4399).

Conclusions

Patients with symptomatic obstructive HCM experienced greater clinical and economic burden than asymptomatic patients in Germany. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicCost of IllnessHealth Care CostsHumansMaleGermanyFemaleRetrospective StudiesMiddle AgedPrevalenceAgedAsymptomatic DiseasesAdultFollow-Up Studies

Stichwörter der Autor:innen

Cardiovascular outcomesClinical and economic burden of illnessHealthcare costsHealthcare resource utilizationSymptomatic and asymptomatic obstructive hypertrophic cardiomyopathy

Autor:innen und Institutionen

  • Department of Internal Medicine III, Institute of Cardiomyopathies, University of Heidelberg, INF 410, 69120, Heidelberg, Germany.
  • DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany.
  • Bristol Myers Squibb, Princeton, NJ, USA.
  • ZEG - Berlin Center for Epidemiology and Health Research GmbH, Berlin, Germany.
  • WIG2 GmbH - Scientific Institute for Health Economics and Health System Research, Leipzig, Germany.
  • Bristol Myers Squibb, Munich, Germany.

Förderung

  • Bristol-Myers Squibb
  • Medizinische Fakultät Heidelberg der Universität Heidelberg

Zitieren

APA

Sedaghat-Hamedani, F., Zema, C. L., Schultze, M., Garcia, T. B., Kossack, N., Borchert, J., Maksabedian Hernandez, E. J., Zhong, Y., Bluhmki, T., Krause, T., Schmoelders, J., & Meder, B. (2025). Clinical and economic burden associated with symptomatic and asymptomatic obstructive hypertrophic cardiomyopathy in Germany. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-025-02776-4

Vancouver

Sedaghat-Hamedani F, Zema CL, Schultze M, Garcia TB, Kossack N, Borchert J, et al. Clinical and economic burden associated with symptomatic and asymptomatic obstructive hypertrophic cardiomyopathy in Germany. Clinical Research in Cardiology. 2025. doi:10.1007/s00392-025-02776-4

BibTeX
@article{SedaghatHamedani2025,
  author = {Sedaghat-Hamedani, Farbod and Zema, Carla L and Schultze, Michael and Garcia, Tarcyane B and Kossack, Nils and Borchert, Julia and Maksabedian Hernandez, Ervant J and Zhong, Yue and Bluhmki, Tobias and Krause, Taryn and Schmoelders, Johanna and Meder, Benjamin},
  title = {Clinical and economic burden associated with symptomatic and asymptomatic obstructive hypertrophic cardiomyopathy in Germany},
  journal = {Clinical Research in Cardiology},
  year = {2025},
  doi = {10.1007/s00392-025-02776-4}
}
Kostenlos starten →